IP Library Granted Patent US 9,532,983
Granted Patent B2
US 9,532,983 · App. 14/448,138 · Granted Jan 3, 2017

Benzofuran compounds, compositions, kits and/or methods thereof

Inventor: Karla-Sue C. Marriott (Savannah, GA)
Assignee: Savannah State University
A61K31/4525A61K45/06C07D307/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,532,983
App. No.
14/448,138
Granted
Jan 3, 2017
Kind
B2
Abstract

Benzofuran compound, composition thereof, kit thereof, and/or method thereof. A benzofuran-2-carboxamide moiety may be N-arylated and/or N-alkylated, and the resulting benzofuran compound may be a sigma receptor ligand that binds to, e.g., a σ1 receptor and/or a σ2 receptor with relatively high affinity and/or selectivity. For example, the benzofuran compound may be 5,6-dimethoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, or 6-methoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide. The composition may include the benzofuran compound and a pharmaceutically acceptable carrier.

Claims (21)

1. A composition comprising:

a pharmaceutically acceptable carrier; and

a compound, wherein the compound is one or more of 5,6-dimethoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, and 6-methoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl) propyl)benzofuran-2-carboxamide.

2. The composition of claim 1 , further including a salt of the compound.

3. The composition of claim 1 , wherein the compound is 5,6-dimethoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide.

4. The composition of claim 1 wherein the compound is one or more of 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide and 6-methoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide.

5. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is in the form of an emulsion, a paste, a cream, a lotion, a gel, jelly, ointment, oil, aerosol, powder, and/or solvent.

6. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is in the form of a liposome, a micelle, a peptide, a synthetic polymer, and/or a natural polymer.

7. The composition of claim 1 , wherein the pharmaceutically acceptable carrier is in the form of a nanomaterial.

8. The composition of claim 1 , wherein the compound is one or more of linked with the pharmaceutically acceptable carrier and physically sequestered by the pharmaceutically acceptable carrier.

9. The composition of claim 1 , wherein one or more of the compound and the pharmaceutically acceptable carrier are functionalized with a ligand for a specific target.

10. The composition of claim 1 , further including at least one other therapeutic compound including one or more of a neurological disease drug and a cancer drug.

11. A kit comprising:

a container; and

a composition including a pharmaceutically acceptable carrier and a compound, wherein the compound is one or more of 5,6-dimethoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide, 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl) benzofuran-2-carboxamide, and 6-methoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl) benzofuran-2-carboxamide.

12. The kit of claim 11 , further including a salt of the compound.

13. The kit of claim 11 , wherein the pharmaceutically acceptable carrier is in the form of an emulsion, a paste, a cream, a lotion, a gel, jelly, ointment, oil, aerosol, powder, solvent, a liposome, a micelle, a peptide, a synthetic polymer, a natural polymer, and/or a nanomaterial.

14. The kit of claim 11 , wherein the compound is one or more of linked with the pharmaceutically acceptable carrier and physically sequestered by the pharmaceutically acceptable carrier, and wherein one or more of the compound and the pharmaceutically acceptable carrier are functionalized with a ligand for a specific target.

15. The kit of claim 11 , further including one or more of an instruction and information regarding at least the compound.

16. The kit of claim 11 , wherein the compound is 5,6-dimethoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide.

17. The kit of claim 11 , wherein the compound is one or more of 3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide and 6-methoxy-3-methyl-N-phenyl-N-(3-(piperidin-1-yl)propyl)benzofuran-2-carboxamide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: MARRIOTT, KARLA-SUE C.
To: SAVANNAH STATE UNIVERSITY
Reel/Frame 033435/0749 →
Continuity (2)
Provisional Application 61860492 · Jul 31, 2013
Related Publication 20150133498A1 · May 14, 2015